Masaru Terasaki1,2, Ryota Kimura3, Atsuhito Kubota3, Hiroyuki Kojima3, Takuji Tanaka4, Hayato Maeda5, Kazuo Miyashita6, Michihiro Mutoh7. 1. School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Hokkaido, Japan terasaki@hoku-iryo-u.ac.jp. 2. Advanced Research Promotion Center, Health Sciences University of Hokkaido, Hokkaido, Japan. 3. School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Hokkaido, Japan. 4. Department of Diagnostic Pathology and Research Center of Diagnostic Pathology, Gifu Municipal Hospital, Gifu, Japan. 5. Faculty of Agriculture and Life Science, Hirosaki University, Aomori, Japan. 6. Laboratory of Biofunctional Material Chemistry, Division of Marine Bioscience, Graduate School of Fisheries Sciences, Hokkaido, Japan. 7. Epidemiology and Preventions Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Abstract
BACKGROUND/AIM: Fucoxanthin (Fx) is a potent anticancer carotenoid, demonstrated by mouse cancer models. We recently showed the decrease of salivary glycine could represent an attenuation of tumor microenvironment (TME) formation in an azoxymethane/dextran sodium sulfate (AOM/DSS) colon cancer mouse model. However, it remains unclear whether the salivary glycine is an indicator for continuous TME suppression of Fx in the mice. MATERIALS AND METHODS: In the present study, we time-dependently analyzed salivary metabolites in AOM/DSS mice, and investigated candidate markers to evaluate the continuous inhibition of colonic TME formation and carcinogenesis in the mice with and without Fx. RESULTS: Fx attenuated the incidence and/or multiplicity of colonic lesions developed in AOM/DSS mice. The number of apoptosis-like cleaved caspase-3high cells was significantly increased, and colonic cancer stem cell-like CD44high/EpCAMhigh cells and cancer-associated fibroblast-like αSMAhigh cells were significantly decreased in colon mucosal tissue by Fx administration. Salivary glycine at 4, 11 and 14 weeks after the final DSS exposure in the Fx-treated mice showed successful and consecutive decreases of 0.5-, 0.4- and 0.7-fold respectively compared to that of control mice. CONCLUSION: Salivary glycine is a valuable indicator that could evaluate sustained efficacy of cancer chemopreventive effects of Fx in AOM/DSS mice. Copyright
BACKGROUND/AIM: Fucoxanthin (Fx) is a potent anticancer carotenoid, demonstrated by mousecancer models. We recently showed the decrease of salivary glycine could represent an attenuation of tumor microenvironment (TME) formation in an azoxymethane/dextran sodium sulfate (AOM/DSS) colon cancermouse model. However, it remains unclear whether the salivary glycine is an indicator for continuous TME suppression of Fx in the mice. MATERIALS AND METHODS: In the present study, we time-dependently analyzed salivary metabolites in AOM/DSS mice, and investigated candidate markers to evaluate the continuous inhibition of colonic TME formation and carcinogenesis in the mice with and without Fx. RESULTS:Fx attenuated the incidence and/or multiplicity of colonic lesions developed in AOM/DSS mice. The number of apoptosis-like cleaved caspase-3high cells was significantly increased, and colonic cancer stem cell-like CD44high/EpCAMhigh cells and cancer-associated fibroblast-like αSMAhigh cells were significantly decreased in colon mucosal tissue by Fx administration. Salivary glycine at 4, 11 and 14 weeks after the final DSS exposure in the Fx-treated mice showed successful and consecutive decreases of 0.5-, 0.4- and 0.7-fold respectively compared to that of control mice. CONCLUSION: Salivary glycine is a valuable indicator that could evaluate sustained efficacy of cancer chemopreventive effects of Fx in AOM/DSS mice. Copyright
Authors: Yunsheng Chen; Shangli Cheng; Aming Zhang; Jie Song; Jie Chang; Kan Wang; Yixin Zhang; Shuijun Li; Haiming Liu; Gabriel Alfranca; Muhammad Aqeel Aslam; Bingfen Chu; Can Wang; Fei Pan; Lijun Ma; Jesús M de la Fuente; Jian Ni; Daxiang Cui Journal: J Biomed Nanotechnol Date: 2018-10-01 Impact factor: 4.099
Authors: Javier Ávila-Román; Sara García-Gil; Azahara Rodríguez-Luna; Virginia Motilva; Elena Talero Journal: Mar Drugs Date: 2021-09-23 Impact factor: 5.118